Amgen Sued On US Stelara Biosimilar After Providing May 2023 Intent
Janssen Alleges Compound And UC Patents Infringed By ABP 654 Biosimilar
With Janssen’s Stelara set to lose its exclusivity in September 2023, the originator is looking to ward off potential biosimilar competition from Amgen by suing the firm for patent infringement in a US district court.
